Although the promising results related to both characterization of tumor antigenicity and inflammation status, no biomarkers other than PD-L1 have been introduced in NSCLC to select patients for first-line treatment with pembrolizumab [1]. Here, CD274 is linked to non-small cell lung carcinoma.